IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

| Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compared Application of: | Compar

## INFORMATION DISCLOSURE STATEMENT UNDER RULE 1.56

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

**PRODUCTS** 

Applicant requests that these documents be considered by the Examiner before issuance of the next action and made of record in this file. The Examiner is also asked to initial and return a copy of the enclosed PTO/SB/08A Form to evidence such consideration.

This Information Disclosure Statement is being filed in accordance with the following provisions:

[X] CFR §1.97(b)(1). Within three months of the filing date of the application. No fee is required.

[X] 37 CFR § 1.97(b)(3). To the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits. No fee is required.

If it is determined that a fee is required as set forth in 37 CFR § 1.17(p) or 1.17(i)(1), or if any additional fees are required, please charge such fee to Deposit Account No. 02-4467. A duplicate copy of this document is enclosed.

Respectfully submitted,

James B. Surber

Registration No. 48,381

BRYAN CAVE LLP

211 North Broadway, Suite 3600

St. Louis, Missouri 63102-2750

(314) 259-2390 (Telephone)

(314) 259-2020 (Facsimile)

Approved for use through 07/31/2006OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JAN 0 2 20

TRADE

institute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known			
Application Number	10/674,582		
Filing Date	September 29, 2003		
First Named Inventor	Rodney G. Wilson		
Group Art Unit			
Examiner Name	Not yet assigned		

_ Sile	٠, ا	<u> </u>				Attorney Docket N		C0104977011	<del>,,,,,</del>	<u>L</u>	
U.S. PATENT DOCUMENTS											
Examiner Initials*	Cite No.1	U.S. Number		nt Code <sup>2</sup> nown)		e of Patentee or Applicant of Cited Document		e of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	A1	US-2003	/0144876A1			Kosinski et al.		7/31/2003			
	A2	US-2003	/0139945A1			Brown et al.		7/24/2003		-	
				j							
						,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
				<b>-</b>							
	-				<u> </u>						
				+	<del>                                     </del>						
	<b>†</b>			1							
				†							
FOREIGN PATENT DOCUMENTS											
Examiner Initials*	Cite No.1			ent Code <sup>5</sup> nown)		Name of Patentee or icant of Cited Document	0	e of Publication of Cited Document MM-DD-YYYY	Pas	es, Columns, Lines, Where Relevant sages or Relevent Figures Appear	T6
				_			_				4
				+							
	<u> </u>				1		<del>-   -</del>			<del>.</del>	1
	<del>                                     </del>			+			+				+
	l			1	L						

Examiner	Date	
Signature	Considered	
	 _	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Attorney Docket Number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application of the property of t

Sheet

Complete if Known

Application Number 10/674,582

Filing Date September 29, 2003

First Named Inventor Rodney G. Wilson

Group Art Unit

Examiner Name Not yet assigned

C018497/0106453

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Examiner Cite T2 Initials\* publisher, city and/or country where published. "FREE Orange Card" pamphlet enrollment form of GLAXOSMITHKLINE Internet enrollment form of TOGETHER RX, LLC C2 "Real Savings. Real Easy." Pamphlet enrollment form of TOGETHER RX, LLC СЗ Patient Assistance Program enrollment form of TAP PHARMACEUTICALS, INC. C4 Patient Assistance Program enrollment form of SOLVAY PHARMACEUTICALS C5 Patient Assistance Program enrollment form of SHIRE US INC. C6 C7 Patient Assistance Program enrollment form of SCHERING C8 Patient Assistance Program form of PURDUE Patient Assistance Program form of ORPHAN MEDICAL C9 C10 Patient Assistance Program form of NOVARTIS C11 Patient Assistance Program form of PROCTER & GAMBLE C12 Patient Assistance Program form of CONNECTION TO CARE C13 Patient Assistance Program form of MGI PHARMA Patient Assistance Program form of LIGAND PHARMACEUTICALS C14 Patient Assistance Program form of FAULDING LABORATORIES C15 Patient Assistance Program form of FIRST HORIZON PHARMACEUTICAL CORPORATION

Examiner	Date	
Signature	Considered	
<u> </u>	<u> </u>	<u> </u>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.